Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain

被引:44
|
作者
Unzue, Andrea [1 ]
Xu, Min [2 ]
Dong, Jing [2 ]
Wiedmer, Lars [2 ]
Spiliotopoulos, Dimitrios [2 ]
Caflisch, Amedeo [2 ]
Nevado, Cristina [1 ]
机构
[1] Univ Zurich, Dept Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland
[2] Univ Zurich, Dept Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
ACETYL-LYSINE INTERACTIONS; SMALL-MOLECULE INHIBITORS; ACUTE MYELOID-LEUKEMIA; BINDING-PROTEIN; DISCOVERY; OPTIMIZATION; ACETYLTRANSFERASE; CBP/P300; I-BET762; THERAPY;
D O I
10.1021/acs.jmedchem.5b00172
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Novel ligands of the CREBBP bromodomain were identified by fragment-based docking. The in silico discovered hits have been optimized by chemical synthesis into selective nanomolar compounds, thereby preserving the ligand efficiency. The selectivity for the CREBBP bromodomain over other human bromodomain subfamilies has achieved by a benzoate moiety which was predicted by docking to be involved in favorable electrostatic interactions with the Arg1173 side chain, a prediction that could be verified a posteriori by the high-resolution crystal structure of the CREBBP bromodomain in complex with ligand 6 and also by MD simulations (see Xu, M.; Unzue, A.; Dong, J.; Spiliotopoulos, D.; Nevado, C.; Caflisch, A. Discovery of CREBBP bromodomain inhibitors by high throughput docking and hit optimization guided by molecular dynamics. J. Med. Chem. 2015, DOI: 10.1021/acs.jmedchem.51300171).
引用
收藏
页码:1350 / 1356
页数:7
相关论文
共 50 条
  • [21] Fragment-Based Drug Discovery in the Bromodomain and Extra-Terminal Domain Family
    Radwan, Mostafa
    Serya, Rabah
    [J]. ARCHIV DER PHARMAZIE, 2017, 350 (08)
  • [22] NMR-Guided fragment-based approach for the design of tRNALys3 ligands
    Chung, Florence
    Tisne, Carine
    Lecourt, Thomas
    Dardel, Frederic
    Micouin, Laurent
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2007, 46 (24) : 4489 - 4491
  • [23] Fragment-Based Discovery of Subtype-Selective Adenosine Receptor Ligands from Homology Models
    Ranganathan, Anirudh
    Stoddart, Leigh A.
    Hill, Stephen J.
    Carlsson, Jens
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (24) : 9578 - 9590
  • [24] NMR-guided fragment-based approach for the design of AAC(6′)-Ib ligands
    Lombes, Thomas
    Begis, Guillaume
    Maurice, Frederique
    Turcaud, Serge
    Lecourt, Thomas
    Dardel, Frederic
    Micouin, Laurent
    [J]. CHEMBIOCHEM, 2008, 9 (09) : 1368 - 1371
  • [25] In Silico Approaches for Fragment-based Drug Design
    Takahashi, Osamu
    Masuda, Yoshiaki
    Muroya, Ayumu
    Furuya, Toshio
    [J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2010, 130 (03): : 349 - 354
  • [26] Fragment-based QSAR: perspectives in drug design
    Salum, Livia B.
    Andricopulo, Adriano D.
    [J]. MOLECULAR DIVERSITY, 2009, 13 (03) : 277 - 285
  • [27] Entropic Fragment-Based Approach to Aptamer Design
    Tseng, Chih-Yuan
    Ashrafuzzaman, Md
    Mane, Jonathan Y.
    Kapty, Janice
    Mercer, John R.
    Tuszynski, Jack A.
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2011, 78 (01) : 1 - 13
  • [28] The ways and means of fragment-based drug design
    Doak, Bradley C.
    Norton, Raymond S.
    Scanlon, Martin J.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2016, 167 : 28 - 37
  • [29] Fragment-based lead discovery: leads by design
    Carr, RAE
    Congreve, M
    Murray, CW
    Rees, DC
    [J]. DRUG DISCOVERY TODAY, 2005, 10 (14) : 987 - 992
  • [30] Applications of ?linkers? in fragment-based drug design
    Wu, Xin
    Zhang, Yuan
    Liu, Songbin
    Liu, Chang
    Tang, Guotao
    Cao, Xuan
    Lei, Xiaoyong
    Peng, Junmei
    [J]. BIOORGANIC CHEMISTRY, 2022, 127